Al Fin, You Sexy Thing!

31 December 2006

Bremelanotide for Female Sexual Dysfunction--Phase 2 Trials

As Bremelanotide gets closer to phase 3 trials, you can sense the revolution building. Some feminists thought Viagra was the revolution, but feminists have no real imagination. Bremelanotide is going to hit modern developed societies like no other drug since the contraceptive pill.

Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the companies have completed enrollment in the pre-menopausal cohort of a Phase 2 "at-home" clinical trial evaluating bremelanotide in pre- and post-menopausal patients experiencing female sexual dysfunction (FSD). The FSD clinical trial is designed to evaluate the initial multiple-dose safety and efficacy of bremelanotide in both pre- and post- menopausal women, and will provide the companies with information that will guide selection of clinical endpoints and estimates of treatment effect size for future clinical trials. The results from this trial are anticipated to be released in calendar year 2007. Bremelanotide is a drug candidate for the treatment of male and female sexual dysfunction and is being developed for regulatory approval and commercialization by Palatin and King Pharmaceuticals.

Bremelanotide is the first compound in a new drug class called melanocortin receptor agonists under development to treat sexual dysfunction. This new chemical entity is being evaluated in Phase 2 clinical trials studying the efficacy and safety profile of varying doses of this novel compound in men experiencing erectile dysfunction (ED) and women experiencing female sexual dysfunction (FSD). The mechanism of action of bremelanotide may offer important benefits over currently available products for the treatment of ED because it acts on the pathway that controls sexual function without acting directly on the vascular system. Clinical data indicates that bremelanotide may be effective in treating a broad range of patients suffering from ED.

The birth control pill separated sex from procreation. The subsequent sociological revolution from that severance has been incalculable. The true aphrodisiacs will separate sexual desire/response from natural preference. In other words, "I'm not in the mood" will prompt the opening of the drug cabinet, instead of a long sexless night.

Rohypnol and alcohol are date rape drugs because they lower the woman's defenses against unwanted sex substantially. Bremelanotide will go much further--it will not only lower the defenses, it will open the gates wide.

Since the issue of the malleability of "free will" is one the FDA may not wish to consider, it is possible the courts will get involved in the final approval of Bremelanotide.

Labels: ,


Post a Comment

Subscribe to Post Comments [Atom]

<< Home

Newer Posts Older Posts